FDA Orders New Eye Risk Warnings for Ozempic and Zepbound
The Honolulu Star-Advertiser reports that the FDA has ordered new eye risk warnings for medications Ozempic and Zepbound.
Honolulu, HI, November 9, 2026 — The U.S. Food and Drug Administration (FDA) has mandated the inclusion of new warnings related to potential eye risks on the labeling for the medications Ozempic and Zepbound. This development was reported by the Honolulu Star-Advertiser.
The specific details regarding the nature of the eye risks that will be highlighted in the updated warnings were not provided in the summary of the report. Similarly, the exact timeline for when these new warnings will be implemented on the medication packaging or distributed to healthcare providers and patients is not yet clear.
Ozempic and Zepbound are widely recognized medications, frequently prescribed for managing type 2 diabetes and weight loss, respectively. Ozempic is manufactured by Novo Nordisk and contains semaglutide. Zepbound, also containing semaglutide, is an FDA-approved medication for chronic weight management and is manufactured by Eli Lilly and Company.
The FDA’s decision to require updated warnings suggests a need for greater awareness among patients and medical professionals concerning potential adverse effects on vision associated with these drugs. The Honolulu Star-Advertiser’s reporting indicates that the agency has taken this step to ensure comprehensive patient safety information is readily available.
Further information regarding the FDA’s order, including the precise language of the new warnings and any associated research or clinical data that prompted this action, is expected to be disclosed as the implementation process moves forward. The scope of the eye risks, whether they are temporary or permanent, and their frequency among users are details that remain to be elaborated upon.
As of the reporting, the specific actions required from manufacturers of Ozempic and Zepbound by the FDA to update their product information have not been detailed. The reporting does not include information on any previous discussions or advisories that may have preceded this formal order, nor does it specify if these warnings are in response to new findings or a review of existing data.
Information concerning potential patient impact, such as guidance on who might be more susceptible to these eye risks or what symptoms to monitor, was also not included in the initial report. The Honolulu Star-Advertiser’s article serves as the primary source for this update on regulatory action concerning these popular medications.
Story summarized from the original created by Google News on news.google.com, see more information here.
